Friday, August 10, 2012

Implementing a Hyperglycemic Management Program for Complex Older Patients


ADA 2012 Conference, presented by Barbara Resnick, MD

-       General principles of diabetes management
o   Older adults with relatively good health should have the same opportunity as younger adults for intensive diabetes management, reduction of risks associated with diabetes, and treatment of comorbid conditions
o   For some older patients, intensive management of diabetes and its complications may be logistically difficult, may not provide benefit, may not be consistent with patient preferences and in some patients, may even be harmful
o   Diabetes management goals and clinical targets should be individualized
-       Clinical evaluation of complex older adults with diabetes
o   Evaluate risk factors for atherosclerotic disease and presence of comorbid diseases
o   Take thorough medication history
o   Assess functional status
o   Screen for geriatric syndromes: use of multiple medications, depression, cognitive impairment, urinary incontinence, injurious falls, and chronic pain
o   Assess need for diabetes education and self-management support, and whether to involve a caregiver
o   Assess resident priorities and preferences
-       Challenges to DM management/ prevention of hyperglycemia
o   Resident-specific issues
o   Provider specific issues
o   System related issues
§  NO direction impact of poor diabetic management à patients don’t feel it
§  Lac of standards or guidelines for optimal management of diabetes across the full aging continuum
§  Behaviour change is never easy…I know I should, but….
§  Practitioners’ ambivalence about the benefits and risks of glycemic control
§  Knowledge deficiencies among direct caregivers/families/residents/non-geriatric focused PCPs
§  Inadequate metabolic monitoring and review of treatment by the practitioner
§  Changing old beliefs as new knowledge is gained
§  Getting the story straight (how much and when did the patient eat?)
-       Tidbits for successful behaviour change
o   Don’t be afraid to address multiple behaviours
§  Addressing multiple behavious allows you to teach general behaviour change principles such as how to cope with barriers, work with a partner, or establish goals and rewards
§  Older individuals tend to choose to change multiple behaviours rather than focus on a single behaviour
§  Providers can change although work off what they believe more so than what they know
-       Process for change
o   Component I
§  Education
·      To assure a philosophy of care that increases awareness and concerns about hyperglycemia
§  Does the environment facilitate management of diabetes and hyperglycemia
·      Equipment
·      Sufficient staffing
·      Exercise equipment and environment to support and encourage physical activity
§  Specific issues to teach to facilitate adherence
·      Caregivers and older adults less likely to be familiar with
o   Atypical presentation of hyperglycemia
o   Give tickler sheets of exactly what to look for
§  Confusion, delirium, feel lousy
§  Blurred vision (eyesight)
§  Feeling very tired
§  Frequent urination
§  Leg cramps
§  More thirsty than usual
§  Weight loss
§  Dry eyes or mouth
§  Weakness
§  Dizziness
§  Drowsiness or confusion/seizures
§  At the institutional level
·      Teach patients/caregivers to assess for underlying cause of episodes of hyperglycemia – be a detective
·      Teach rational for testing sugars at times
·      Teach recognition of associated complications from DM (wounds, fungal infection, memory changes)
·      Review drug side effects à compliance
·      Explore behaviours: ETOH, diet, exercise, meds
o   Focused on outcomes – decrease wine and cake intake
o   Repeat, repeat, and repeat – each visit give hyperglycemia prevention tidbits, trivia questions to staff
o   What to eat and what not to eat
o   What exercise to do and what not to do
·      EASY website
·      NIA workout to go
o   Component II
§  Evaluation of the resident and goal setting
§  Establish goals for residents and settings
·      Look at status of individual and mean glucose
·      Look at hospitalization/ER visits for individual settings
·      Decreasing fingerpricks?
·      Survey issues around medication management
§  Need to help establish and accept realistic treatment goals
·      Explore goals with residents/family – which way do they want to go?
·      Optimal QOL – no versus some dietary management; some exercise; ETOH use, medication adherence
·      Avoidance of hypo or marked hyperglycemia
·      Control of complications?
·      Decreased hospitalizations
·      Focus on symptom management
o   Tie symptoms (e.g., increased urination, dry mouth, confusion) to sugars
·      Interpersonal Interactions
o   Verbal encouragement
§  Start with encouragement and reinforcement
§  Find a buddy/family member to help motivate
§  Physical encouragement via performance – tie adherence to positive outcomes (weight loss à less hyperglycemic episodes, reduce meds, etc)
§  If no change in 6 weeks to 6 months (depending on visit schedule) move on to tough love
§  Encouragement tied to outcomes
§  Threat of meds
·      Eliminate the unpleasant sensations
o   Address the common ones
§  Pain
§  Fear of falling
§  Staff fear causing hypoglycemia
§  Fatigue
§  Hunger
§  Finances
§  Ask what stops them
§  Observe what stops them
§  Differentiate barriers from excuses
·      Role modeling
o   Share your own challenges and successes in diet, exercise and mediation adherence
o   Eat, play, and engage in physical activity with residents and encourage families to do likewise
·      Weigh real world issues with medication management
o   Carefully weigh the benefit/risk of medications to determine how badly this is needed
o   Can alternative methods of administration be considered?
§  Diet vs. pill, insulin pens, daily dosing
o   Component III
§  Mentoring and motivating of everyone

Wednesday, July 25, 2012

Patient-Centered Approach to Type 2 Diabetes

Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Glycemic Targets:

1. Target HbA1c < 7.0%

  • In most patients to reduce the incidence of microvascular disease
  • Mean plasma glucose of ~ 8.3-8.9 mmol/L
  • Fasting and premeal glucose < 7.2mmol/L
  • Postprandial glucose < 10 mmol/L

2. Target more stringent HbA1c (e.g., 6.0-6.5%)

  • In selected patients such as short disease duration, long life expectancy, no significant cardiovascular disease (CVD) if this can be achieved without significant hypoglycemia or other adverse effects of treatment

 

3. Target less stringent HbA1c (e.g., 7.5-8.0% or even slightly higher)

  • In patients with history of severe hypoglycemia, limited life expectancy, advanced complications, extensive comorbid conditions and those in whom the target is difficult to attain despite intensive self-managment education, repeated counseling, and effective doses of multiple gluocse-lowering agents, including insulin.

 

Reference:

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;25:1364-79

Friday, July 13, 2012

Exendin - A New Incretin?

ADA June 2012 Conference


Alpha cells and the origin of glucagon-like sequences and their receptors

David M. Irwin, Department of Laboratory Medicine and Pathobiology, University of Toronto


Summary of presentation:

Incretin Hormones – 2 known human incretin hormones
-          Glucagon-like peptide 1 (GLP-1)
-          Glucose-dependent insulinotropic peptide (GIP)

Other incretins = Exendin
-          Long acting GLP-1 analogue
o   Acts through the GLP-1 receptor
o   Have increased circulating half-life
o   Synthetic version marketed
-          From the venom of a lizard (Gila monster)
-          No known orthologs in vertebrates, not a product of the proglucagon gene
-          Anole Lizard Exendin – sequence of peptides are not similar to GLP-1 or GIP (human genome)
-          Other animals had similar exendin to lizard (chicken, turkey, duck, zebra finch, xenopus)
-          Exendin 1, 2, 3,and 4 sequences – exendin 3 and 4 are GLP-1 like in their sequence and function; exendin 1 and 2 similar to the are GIP-like in sequence and function
-          Expression of the exendin gene in the chicken and xenopus brain – who knows what it is duing there?
-          No exendin gene in human genome!
-          Exendin genes are found in birds, reptiles and frogs
-          No obvious candidate receptor for exendin; glucagon, GLP1, GLP2, and GIP act through related receptors
-          There are novel group of receptors present in fish, reptiles, birds that are NOT present in mammals – why do mammals not have this gene?
-          GLP1 receptors not found in fish
-          GCGR – duplicated in fish (glucagon receptors)
-          GLP2R – single copy in all species
-          GIPR – no intact gene found in birds
-          GRLR – not found in mammals (glucagon-receptor-like-receptors

Conclusion
o   Genomic data useful for identifying new genes
o   Continues to yield surprises
o   Hormone and receptor families are larger and more complex
-          Open questions
o   What does exendin do in other vertebrates?
o   Is GRLR the receptor for exendin?
o   Why do humans (all mammals) not have Exendin/GRLR?
o   What ligand/receptor has replace the function of Exendin/GRLR in mammals?


Friday, June 22, 2012

Omega-3 Fatty Acids & CV outcomes in patients with dysglycemia

Clinical Question
In patients at high risk for cardiovascular events and have impaired fasting glucose, impaired glucose tolerance, or diabetes, what are the benefits (death from cardiovascular causes) and risks (adverse effects) of 1-g n-3 fatty acids (containing at least 900mg of ethyl esters) compared to placebo at 6.2 years of therapy?

Answer
Efficacy Outcomes
In 12,536 patients (n=6281 in n-3 fatty acid group and n=6255 in placebo group), there was no statistical difference in the primary outcome of death from cardiovascular causes after a median follow-up of 6.2 years.  All secondary outcomes (mycoardial infarction, stroke, death from cardiovascular causes, death from any cause/arrhythmia, hospitalization for heart failure, revascularization procedure, angina, limb or digit amputation for ischemia, and hospitalization for any cardiovascular cause) were all non-significant.  By the end of the trial, patients in the group receiving n-3 fatty acids had a mean reduction in the triglyceride level of 0.16mmol/L as compared to placebo (p<0.001).  No significant between-group differences in the levels of other lipid fractions, plasma glucose levels, glycated hemoglobin levels, blood pressure, or heart rate.

Adverse Effects
The most commonly reported reasons for permanently stopping a study drug was abdominal discomfort (n=32 (0.51%) in the n-3 fatty acid group and 18 (0.29%) in the placebo group), lower gastrointestinal symptoms (n=14 in n-3 fatty acid group and 24 in the placebo group).  Bleeding was reported in 57 (0.91%) patients receiving n-3 fatty acids, as compared with 65 (1.04%) patients in the placebo group, with intracranial bleeding reported in 42 patients, and 51 patients, respectively.



Reference:  The ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012.published on June 11, 2012.